TABLE III.

Postoperative outcomes

Characteristic	All patients (n=156)	Sarcopenia			Myosteatosis			Visceral obesity
		Yes (n=24)	No (n=132)	p Value	Yes (n=131)	No (n=25)	p Value	Yes (n=64)	No (n=92)	p Value
Complicationsa [n (%)]
All	51 (32.7)	15 (62.5)	36 (27.3)	0.001	50 (38.2)	1 (4.0)	0.002	23 (35.9)	28 (30.4)	0.471
Stage 2	26 (16.7)	9 (37.5)	18 (13.6)		26 (19.8)	0 (0.0)		13 (20.3)	13 (14.1)
Stage 3a	17 (10.9)	5 (20.8)	12 (9.1)		16 (12.2)	1 (4.0)		6 (9.4)	11 (12.0)
Stage 3b	7 (4.5)	1 (4.2)	6 (4.5)		7 (5.3)	0 (0.0)		3 (4.7)	4 (4.3)
Stage 4	1 (0.6)	0 (0.0)	1 (0.8)		1 (0.8)	0 (0.0)		1 (1.6)	0 (0.0)
Inflammatory	19 (12.2)	4 (16.7)	15 (11.4)	0.695	19 (14.5)	0 (0.0)	0.089	13 (20.3)	6 (6.5)	0.01
Exsufflation time (days)				0.136			0.26			0.574
Median	3	3	3		3	3		3	3
IQR	(3–4)	(3–4)	(3–4)		(3–4)	(2–4)		(3–4)	(3–4)
Gastric drainage (mL)				0.216			0.209			0.837
Median	80	140	80		70	130		80	80
IQR	(25–247)	(36–408)	(21–215)		(22–210)	(30–300)		(30–290)	(22–232.5)
Abdominal drainage (mL)				0.467			0.003			0.609
Median	525	560	520		580	275		545	515
IQR	(275–1180)	(324–1545)	(267–1080)		(300–1250)	(151–419)		(270–1260)	(277–1045)
Albumin use (g)				0.002			0.037			0.85
Median	40	70	35		40	0		40	30
IQR	(0–60)	(23–70)	(0–60)		(0–60)	(0–50)		(0–75)	(0–60)
Postoperative hospitalization (days)				0.065			0.006			0.135
Median	8	11	8		8.5	7		9	8
IQR	(7–11.8)	(7–17)	(7–11)		(7–12)	(6–8)		(7–12)	(6–10.5)

^aAssessed by Clavien–Dindo grade.

IQR = interquartile range.